Notícias e Atividades da Arcturus Therapeutics

Arcturus Therapeutics é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Arcturus Therapeutics é uma empresa listada sob o símbolo ARCT (US).

Veja o organograma con seus 32 executivos principais

Biografias mais buscadas da Arcturus Therapeutics

• Joseph Payne, Director, President and Chief Executive Officer
• Jing Marantz, Director
• Edward Holmes, Director

Recentes movimentos de executivos em Arcturus Therapeutics

• Moncef Slaoui antes Director, foi promovido a Chairman Designate  (Notícia publicada em 6 de fevereiro de 2025).

Criar um alerta
para seguir os movimentos de executivos da Arcturus Therapeutics.

Arcturus Therapeutics possui 2.350 concorrentes concorrentes Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) e Lonza (Suíça).

Popular M&A news in Biotecnologia

• Sirius Therapeutics acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 16 de junho de 2025).
• BioNTech has announced the acquisition of CureVac  (publicado em 12 de junho de 2025).
• SpliceBio acaba de anunciar uma arrecadação de fundos de 135 milhões de dólares. (publicado em 11 de junho de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships da WIRB-Copernicus Group
• Jasbir Seehra - Chief Executive Officer and Chairman of the Board da Keros Therapeutics
• Deepika Verma - Associate Director of Data Science and Digitalization da Wheeler Bio

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Arcturus Therapeutics

• Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022 | Arcturus Therapeutics, Inc.
• Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Arcturus Therapeutics, Inc.
• Recipharm signs agreement with Arcturus Therapeutics to support the manufacture of LUNAR®-COV19 (ARCT-021) vaccine candidate | Arcturus Therapeutics, Inc.
• Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency | Arcturus Therapeutics, Inc.
• Arcturus Therapeutics to Present at Guggenheim’s Vaccines and Infectious Diseases Conference | Arcturus Therapeutics, Inc.
• Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences | Arcturus Therapeutics, Inc.
• Arcturus Therapeutics Announces Preclinical Publication of its COVID-19 Vaccine Candidate | Arcturus Therapeutics, Inc.
• Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health | Arcturus Therapeutics, Inc.
• Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study | Arcturus Therapeutics, Inc.
• Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate Update | Arcturus Therapeutics, Inc.
• View more press releases Close

Redes sociais sobre Arcturus Therapeutics

• Arcturus Therapeutics na Wikipedia, Google News e Yahoo Finance
• Arcturus Therapeutics na LinkedIn, Twitter e YouTube